- GLP-1 microdosing has no standard medical definition and no FDA-approved dose schedule.
- A clinician can keep a patient at a lower approved dose for a clinical reason. This individual dose adjustment is not the same as a commercial microdosing claim.
- Large semaglutide and tirzepatide trials tested defined treatment schedules. They did not test the very small doses promoted by microdose programs.
- The lowest advertised first payment can exclude later subscription costs. Compare the total program cost, medication source, pharmacy, and clinical follow-up.
"GLP-1 microdosing" is a marketing term. It is not a standard clinical dose category.
The term can describe several different practices. One provider can mean a slow start. Another can mean a dose below the approved starting dose. A third can mean longer gaps between injections. These practices do not have the same evidence.
This article explains the difference between approved treatment, individual clinical adjustment, and a commercial microdose program. It does not give dose instructions.
There is no standard definition
FDA-approved GLP-1 products have specific prescribing information. The current Wegovy prescribing information gives defined starting, escalation, and maintenance schedules for semaglutide. The Zepbound prescribing information does the same for tirzepatide.
A prescriber can adjust treatment when a patient has side effects or another clinical need. This is individualized care. It does not create evidence for every program that uses the word "microdose."
Before a person compares programs, the provider must answer three questions:
- What medicine is prescribed?
- Is it an FDA-approved product or a compounded drug?
- What clinical rule determines when the treatment changes?
Without these answers, the word "microdose" gives little useful information.
What the major trials tested
The large weight-loss trials did not test commercial microdose programs.
The STEP 1 trial enrolled 1,961 adults. It tested once-weekly semaglutide with a defined escalation to the studied maintenance treatment. The average weight change at 68 weeks was 14.9% with semaglutide and 2.4% with placebo.
The SURMOUNT-1 trial enrolled 2,539 adults. It tested defined tirzepatide treatment groups. Average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.
These results show that semaglutide and tirzepatide can produce substantial weight loss under studied conditions. They do not show that a much smaller or less frequent dose gives the same result.
What is known about staying at a lower dose?
Some patients respond before they reach a maintenance dose. Some patients need a slower change because of adverse effects. A licensed prescriber can make an individual decision.
This clinical fact is often used to support a broader claim: that very small doses give most of the benefit with few adverse effects. Large controlled trials have not established that claim.
The two statements are different:
- Supported: clinicians can individualize treatment within medical practice.
- Not established: a commercial microdose schedule gives durable weight loss or long-term health benefits comparable with approved schedules.
Compounded products add another question
Many microdose programs use compounded semaglutide or tirzepatide. Compounded drugs are not FDA-approved generic drugs.
FDA's current unapproved GLP-1 safety page states that compounded products do not receive FDA review for safety, effectiveness, or quality before marketing. As of May 31, 2026, FDA had received 990 adverse-event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. A report does not prove that the product caused the event, and FDA says these events are probably underreported.
FDA has also reported measurement errors with compounded semaglutide. Some people received five to 20 times the intended amount because concentrations, syringes, milligrams, milliliters, and "units" caused confusion.
Small intended amounts do not remove measurement risk. In some cases, a small volume can make accurate measurement more difficult.
Does microdosing reduce adverse effects?
Gastrointestinal adverse effects are common with GLP-1 treatment. Slow escalation is already part of approved schedules because tolerability matters.
A smaller amount can reduce exposure, but three uncertainties remain:
- It may also reduce effectiveness.
- The best long-term amount is not known for a commercial microdose schedule.
- The actual concentration and measurement process can differ for a compounded vial.
A provider must not promise that a patient will have no adverse effects. In March 2026, FDA announced warning letters to 30 telehealth companies for false or misleading compounded-GLP-1 claims. The agency objected to claims that implied compounded products were the same as FDA-approved drugs.
What does a microdose program cost?
The price has two parts: the first payment and the continuing cost.
In July 2026, Noom's official microdose page advertised a $79 initial payment and a continuing price of $179 per month. The page states that medication, ongoing care, and program access are included if a clinician prescribes treatment.
PeptidePrices lists Telos RX with microdosed tirzepatide from $69 for the first month. This is an introductory price, not a verified continuing monthly price.
Prices can change without notice. Compare these items before payment:
| Cost item | Question to ask |
|---|---|
| Continuing subscription | What will the second and third months cost? |
| Medication | Is it included, and what product can the clinician prescribe? |
| Pharmacy and shipping | Which licensed pharmacy dispenses it, and is cold shipping included? |
| Supplies and laboratory tests | Are needles, visits, and required tests included? |
| Cancellation | Is there a minimum term or prepaid commitment? |
The lowest first-month number is not the total treatment cost.
Provider checks
Use these checks for any GLP-1 microdose offer:
- A licensed clinician reviews the patient's history before prescribing.
- The program names the medicine and states whether it is compounded.
- The dispensing pharmacy is licensed for the patient's state.
- The instructions use clear units and match the supplied syringe or device.
- The provider gives a clear route for adverse-effect questions and urgent care.
Do not use a product sold as a research chemical for personal treatment.
Bottom line
GLP-1 microdosing is popular, but it is not a defined or FDA-approved treatment schedule. The best evidence for semaglutide and tirzepatide comes from large trials that used defined schedules. Those trials cannot prove the claims of a commercial microdose program.
A lower dose can be a valid individual decision under medical care. It is not proof that all low-dose programs are effective, safer, or lower in total cost.
Related pages: compare weight-loss telehealth providers, semaglutide versus tirzepatide versus retatrutide, and peptides for women's weight loss.
Sources
- Wegovy prescribing information
- Zepbound prescribing information
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA concerns with unapproved GLP-1 products
- FDA alert about compounded-semaglutide dose errors
- FDA telehealth warning-letter announcement
- Noom Microdose GLP-1Rx program and price
Educational information only. This article does not recommend a medicine or dose. A licensed clinician must make treatment decisions for an individual patient.